Related Experiment Video
Updated: Jul 17, 2025
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in
Francesco Giangiacomi1,2, Andrea Faggiano1,2, Daniela Cardinale3
1Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Purpose:
To describe the efficacy and safety of sodium-glucose cotransporter 2 inhibitors as a specific treatment for anthracycline-related cardiac dysfunction in a small real-world population.
Methods:
Seven patients with anthracycline-related cardiac dysfunction were clinically and echocardiographically evaluated before and after the introduction of sodium-glucose cotransporter 2 inhibitors.
Results:
After a median period of 24 weeks with uninterrupted sodium-glucose cotransporter 2 inhibitors treatment, a significant clinical improvement was observed with at least one New York Heart Association Functional Class (NHYA FC) improvement in all patients (median NYHA FC: I vs. III, p < 0.010). A noteworthy left ventricular reserve remodeling (median left ventricular end diastolic volume indexed: 53 vs. 82.5 ml/m2, p = 0.018; median left ventricular ejection fraction: 50% vs. 40%, p = 0.17) was also observed. Sodium-glucose cotransporter 2 inhibitors therapy was well tolerated by every patients; no cases of discontinuation or relevant side effects were observed.
Conclusion:
Sodium-glucose cotransporter 2 inhibitors induce a significant clinical improvement and left ventricular reserve remodeling in patients affected by anthracycline-related cardiac dysfunction.
Insights
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) significantly improved cardiac function in patients with anthracycline-related cardiac dysfunction. This real-world study found SGLT2i therapy to be safe and well-tolerated, showing promising results for this patient group.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Anthracycline chemotherapy can lead to significant cardiac dysfunction.
- Existing treatments for anthracycline-related cardiac dysfunction have limitations.
Observation:
- Seven patients with anthracycline-related cardiac dysfunction were treated with sodium-glucose cotransporter 2 inhibitors (SGLT2i).
- Clinical and echocardiographic parameters were assessed before and after SGLT2i initiation.
Findings:
- All patients showed significant clinical improvement, with a median New York Heart Association Functional Class improvement from III to I (p < 0.010).
- Left ventricular reserve remodeling was observed, indicated by changes in end-diastolic volume (p = 0.018).
- SGLT2i therapy was well-tolerated, with no discontinuations or significant side effects.
Implications:
- SGLT2 inhibitors demonstrate efficacy in improving clinical outcomes for patients with anthracycline-induced cardiac dysfunction.
- These findings suggest SGLT2 inhibitors as a potential therapeutic option for managing chemotherapy-related cardiotoxicity.
- Further research with larger cohorts is warranted to confirm these promising results.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
08:47Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:26Heart Failure Drugs: Inotropic Agents
01:30Heart Failure V: Medical Management
01:29Cardiomyopathy V: Interprofessional Care
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:30Cardiomyopathy II: Dilated Cardiomyopathy